SOURCE: MedaSorb Technologies Corporation

May 01, 2007 08:00 ET

MedaSorb Technologies Corporation Begins Trading on Frankfurt Stock Exchange

MONMOUTH JUNCTION, NJ -- (MARKET WIRE) -- May 1, 2007 -- MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE), a medical device company that engages in the research and development of an adsorbent platform technology for removal of toxins from blood and physiologic fluids, is pleased to announce that its shares are now listed for trading on the Frankfurt Stock Exchange, effective immediately. MedaSorb's trading symbol on the Frankfurt Exchange is HQE.FSE and its WKN (German Security Code) is A0KEY3.

"Listing on the Frankfurt Exchange will allow current and potential European shareholders of MedaSorb to trade our shares within the European time zones and in local currency. This will increase our corporate profile with both private and institutional investors in Germany and across Europe," said Al Kraus, MedaSorb CEO. "This opportunity is part of our strategy to develop synergy between a global shareholder base and the commercialization of our potential products." Shares traded on the Frankfurt Stock Exchange do not have an effect on MedaSorb's total shares outstanding.

About MedaSorb

MedaSorb Technologies Corporation is a medical device company, preparing to commercialize blood purification technology that effectively removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb™ and BetaSorb™, are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. Management believes the potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short- and long-term treatment of kidney failure. MedaSorb is headquartered in Monmouth Junction, New Jersey.

Safe Harbor Statement

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at

Contact Information